We found that Class 2, which had a higher fraction of anti-tumor cells such as CD8+ T cells and activated CD4+ memory T cells, had a better prognosis compared to Class 1, which had comparable stromal scores and fractions of immunosuppressive cells, such as Treg cells and M2 macrophages. The gene discussed is CD8A; the disease is neoplasm.